Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Recruiting 6Completed 6Active not recruiting 4Unknown 2Terminated 2Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 4Neoplasms 1Lung Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 438Carboplatin 321Nivolumab 293Cyclophosphamide 285Specimen Handling 257Paclitaxel 249Magnetic Resonance Spectroscopy 249Cisplatin 248Radiotherapy 218Dexamethasone 183Gemcitabine 177Biopsy 177durvalumab 169atezolizumab 149Doxorubicin 140Rituximab 138Lenalidomide 135Docetaxel 131Ipilimumab 130Bevacizumab 128Radiation 121Capecitabine 117Etoposide 116Oxaliplatin 114Fluorouracil 110Pemetrexed 109Radiosurgery 108fludarabine 106venetoclax 102Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × tepotinib × Clear all
NCT05782361 2026-04-24

POTENT

Institute of Cancer Research, United Kingdom

Phase 1 Active not recruiting
19 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02864992 2026-04-13

VISION

EMD Serono

Phase 2 Active not recruiting
337 enrolled 13 charts 2 FDA
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06083857 2026-03-11

PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
3 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03940703 2026-02-27

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

EMD Serono

Phase 2 Active not recruiting
140 enrolled 47 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡